SPY314.38-1.80 -0.57%
DIA257.24-3.48 -1.33%
IXIC10,547.75+55.25 0.53%

BrainStorm Expands Clinical Pipeline To Evaluate NurOwn For The Treatment Of Alzheimer's Disease

Protocol for the proposed multi-national trial has been submitted for EU regulatory approval Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer's Disease program on July

Benzinga · -

Protocol for the proposed multi-national trial has been submitted for EU regulatory approval
Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer's Disease program on July 8, 2020 at 8:15 AM ET

NEW YORK, June 24, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical program focused on the development of NurOwn® as a treatment for Alzheimer's disease. As part of the newly announced program, the Company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease.